Ocular Therapeutix is a biopharmaceutical company that develops and commercializes therapies for diseases and conditions of the eye. The company's lead product candidate, DEXTENZA, is a corticosteroid that is used to treat post-surgical ocular inflammation and pain. Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, Massachusetts. The company is publicly traded on the NASDAQ under the ticker symbol OCUL.